Association of Metabolic Syndrome with Decreased Glomerular Filtration Rate among 75,468 Chinese Adults: A Cross-Sectional Study

Song, Hui; Wang, Xiuying; Cai, Qingsheng; Ding, Wei; Huang, Shuiping; Zhuo, Lang

doi:10.1371/journal.pone.0113450

Cited by 25 publications

(39 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This result was similar to those in previous reports by Song et al [31] and Kang et al [5] However, no positive association between elevated plasma glucose, elevated WC, and CKD was shown in a cross-sectional study of 6,217 U.S. adults [32]. In another study, elevated TG and obesity were regarded as noncritical components of metabolic syndrome [31]. The multivariate-adjusted ORs of decreased GFR were not significant for those with 1 or 2 noncritical components (versus zero components).…”

Section: Metabolic Syndrome and Chronic Kidney Diseasesupporting

confidence: 94%

“…Kang et al [5]also demonstrated a 1.53-fold increased ORs for CKD in Koreans with metabolic syndrome based on the general health screening data of 10,253,085 participants. Consistent with these findings, the positive effects of metabolic syndrome on the prevalence of CKD were shown in several studies [6][7][8]31]. In the present study, we showed that metabolic syndrome was significantly associated with a 1.49-fold increased OR for CKD.…”

Section: Metabolic Syndrome and Chronic Kidney Diseasesupporting

confidence: 93%

“…The strength of association between metabolic syndrome and the development of CKD increased progressively as the number of components increased from ≤1 to 4. This result was similar to those in previous reports by Song et al [31] and Kang et al [5] However, no positive association between elevated plasma glucose, elevated WC, and CKD was shown in a cross-sectional study of 6,217 U.S. adults [32]. In another study, elevated TG and obesity were regarded as noncritical components of metabolic syndrome [31].…”

Section: Metabolic Syndrome and Chronic Kidney Diseasesupporting

confidence: 91%

See 2 more Smart Citations

Combined Association of Serum Uric Acid and Metabolic Syndrome with Chronic Kidney Disease in Hypertensive Patients

Dai

Lu²,

Tang³

et al. 2016

Kidney Blood Press Res

View full text Add to dashboard Cite

Background/Aims: Chronic kidney disease (CKD) is one of the major complications of hypertension. It is not only associated with the future burden of end-stage renal disease but also affects mortality and cardiovascular outcomes caused by hypertension. To help understand the pathogenesis and early prevention of progressive CKD, this large-scale study is designed to determine the complex association between serum uric acid (SUA), metabolic syndrome and the prevalence of CKD in hypertensive patients. Methods: A total of 19,848 hypertensive subjects were enrolled in this cross-sectional study. Patients with proteinuria and/or an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m² were considered CKD cases. Results: Hypertensive subjects with CKD had a higher prevalence of hyperuricemia and metabolic syndrome, as well as higher levels of SUA, BMI, waist circumference (WC), SBP, DBP, TG, fasting blood glucose and lower levels of HDL-C. Compared to patients without CKD, the multivariate-adjusted odds ratios [ORs, 95% confidence interval (CI)] for CKD patients were 2.30 (2.02-2.63) for hyperuricemia, 1.21 (1.04-1.41) for abdominal obesity, 1.21 (1.06-1.38) for elevated TG, 1.29 (1.06-1.56) for low HDL-C, 1.54 (1.36-1.75) for elevated fasting glucose, and 1.49 (1.30-1.71) for metabolic syndrome. Increasing SUA levels and number of individual metabolic syndrome components were associated with an increased prevalence of CKD. Compared with patients classified in the lowest SUA categories and with ≤1 metabolic syndrome components, subjects with HUA and 4 metabolic syndrome components had a 5.77-fold increased OR for CKD based on the multivariate-adjusted analysis. Conclusion: Both elevated SUA and metabolic syndrome are associated with an increased prevalence of CKD in hypertensive subjects. Subjects with higher SUA and sum of individual metabolic syndrome components simultaneously have a higher prevalence of CKD.

show abstract

Section: Metabolic Syndrome and Chronic Kidney Diseasesupporting

confidence: 94%

Section: Metabolic Syndrome and Chronic Kidney Diseasesupporting

confidence: 93%

Section: Metabolic Syndrome and Chronic Kidney Diseasesupporting

confidence: 91%

See 1 more Smart Citation

Combined Association of Serum Uric Acid and Metabolic Syndrome with Chronic Kidney Disease in Hypertensive Patients

Dai

Lu²,

Tang³

et al. 2016

Kidney Blood Press Res

View full text Add to dashboard Cite

show abstract

“…14,25 More recently, obesity, as an emerging threat, has also played a major role in the progression of CKD. 5,26 Though in multivariable analysis, association of BMI with CKD turned positively on a certain level, as the case in DBP, the deep going research showed male and female have thus opposite effects on the links between BMI and decreased eGFR, which can especially be seen from the chart ( Figure 1F). Though we have found obesity is a noncritical factor previously, 5 the U-shaped association between BMI and decreased eGFR is also presented in multivariable analysis.…”

Section: Discussionmentioning

confidence: 87%

“…4 Therefore, it is vital to better understand the pathogenesis of CKD so as to formulate prophylactic strategies. 5 Metabolic syndrome (MetS), characterized by hypertriglyceridemia, abdominal obesity, depressed serum high-density lipoprotein cholesterol (HDL-C), diabetes mellitus, and hypertension, is commonly found in CKD sufferers. 6,7 Substantial evidence confirmed that MetS and its contributors play a critical role in the progression of CKD.…”

Section: Introductionmentioning

confidence: 99%

Metabolic syndrome does not always play a critical role in decreased GFR

Cai

Wang

et al. 2016

Renal Failure

Self Cite

View full text Add to dashboard Cite

Background There is a paucity of literature available as to the relationship between different levels of each metabolic syndrome (MetS) component and decreased GFR. In the present study, we aimed to demonstrate whether MetS always plays a critical role in decreased GFR. Methods A crosssectional study was conducted between February 2010 and September 2012, with 75,468 adults enrolled undergoing measurements of blood pressure as well as tests of blood and urine samples. Univariate and multivariable logistic regression analyses were performed to estimate the odds ratio (OR) with 95% confidence intervals (CI), and the chi-square test was used for categorical variables and described as a percentage. Results Of the 75,468 participants, 350 (0.5%) subjects met criteria for the decreased GFR, with a mean age of 48.79 ± 13.76 years. After adjustment for age, diastolic blood pressure and high-density lipoprotein were inversely related to decreased estimated glomerular filtration rate (eGFR) in multivariable analyses, with an OR (95% CI) of 0.57 (0.39-0.84) and 0.41 (0.24-0.72), respectively. The prevalence rate of CKD in critical group was 0.73% (154 of 21,127) and 0% (0 of 370) in noncritical group. In analysis stratified by the type of MetS components, the differences in noncritical group and the reference group were not statistically significant ( 2 ¼ 1.349, p40.05). Conclusions MetS does not always play a critical role in decreased GFR, with different levels of individual components of MetS exerting idiosyncratic effects in decreased eGFR. In fact, patients with abnormal body mass index, high triglycerides, and elevated fasting plasma glucose would not have impact on decreased GFR.

show abstract

Association of cardiorenal biomarkers with mortality in metabolic syndrome patients: A prospective cohort study from NHANES

Gao,

Jia,

et al. 2024

Chronic Diseases and Translational Medicine

View full text Add to dashboard Cite

ObjectivesApproximately 20%–25% of the global adult population is affected by metabolic syndrome (MetS), highlighting its status as a major public health concern. This study aims to investigate the predictive value of cardiorenal biomarkers on mortality among patients with MetS, thus optimizing treatment strategies.MethodsUtilizing data from the National Health and Nutrition Examination Survey (NHANES) cycles between 1999 and 2004, we conducted a prospective cohort study involving 2369 participants diagnosed with MetS. We evaluated the association of cardiac and renal biomarkers with all‐cause and cardiovascular disease (CVD) mortality, employing weighted Cox proportional hazards models. Furthermore, machine learning models were used to predict mortality outcomes based on these biomarkers.ResultsAmong 2369 participants in the study cohort, over a median follow‐up period of 17.1 years, 774 (32.67%) participants died, including 260 (10.98%) from CVD. The highest quartiles of cardiac biomarkers (N‐terminal pro‐B‐type natriuretic peptide [NT‐proBNP]) and renal biomarkers (beta‐2 microglobulin, [β2M]) were significantly associated with increased risks of all‐cause mortality (hazard ratios [HRs] ranging from 1.94 to 2.06) and CVD mortality (HRs up to 2.86), after adjusting for confounders. Additionally, a U‐shaped association was observed between high‐sensitivity cardiac troponin T (Hs‐cTnT), creatinine (Cr), and all‐cause mortality in patients with MetS. Machine learning analyses identified Hs‐cTnT, NT‐proBNP, and β2M as important predictors of mortality, with the CatBoost model showing superior performance (area under the curve [AUC] = 0.904).ConclusionCardiac and renal biomarkers are significant predictors of mortality in MetS patients, with Hs‐cTnT, NT‐proBNP, and β2M emerging as crucial indicators. Further research is needed to explore intervention strategies targeting these biomarkers to improve clinical outcomes.

show abstract

Association of Metabolic Syndrome with Decreased Glomerular Filtration Rate among 75,468 Chinese Adults: A Cross-Sectional Study

Cited by 25 publications

References 27 publications

Combined Association of Serum Uric Acid and Metabolic Syndrome with Chronic Kidney Disease in Hypertensive Patients

Combined Association of Serum Uric Acid and Metabolic Syndrome with Chronic Kidney Disease in Hypertensive Patients

Metabolic syndrome does not always play a critical role in decreased GFR

Association of cardiorenal biomarkers with mortality in metabolic syndrome patients: A prospective cohort study from NHANES

Contact Info

Product

Resources

About